Modest Alcohol Consumption Will Not Protect Against Obesity, T2DM Risk
An investigation explored dose-dependent effects of alcohol consumption of type 2 diabetes mellitus and obesity risk.
Diagnosis & Disease Information
Higher Oral Semaglutide Doses Superior for Reducing HbA1c and Bodyweight
Efficacy, safety, and tolerability of higher investigational doses of oral semaglutide vs the standard 14-mg dose were evaluated among patients with inadequately controlled type 2 diabetes.
Cinnamon Improves Blood Sugar Control in Type 2 Diabetes/Polycystic Ovary Syndrome
Researchers performed a meta-analysis study to determine the effects of cinnamon on glycemic control in patients with T2D or PCOS.
AHA/ACC Release Updated Guidelines for Chronic Coronary Disease
Several associations, including the AHA, ACC, and NLA, have issued new guidelines for management of patients with chronic coronary disease.
Oral Semaglutide 50 mg Reduces Bodyweight in Adults Without Type 2 Diabetes
A phase 3 clinical trial examined the efficacy of semaglutide 50 mg for treating overweight and obesity in adults without type 2 diabetes.
SGLT2 Inhibitors Lower the Risk for Gout Flares
Investigators compared sodium-glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP-4is) in a propensity-score matched group of patients with gout and type 2 diabetes.
National Lipid Association Meeting Updates: Lifestyle Interventions, Metabolic Syndrome, and Diabetes
Highlights from National Lipid Association Scientific Sessions 2023 include metabolic syndrome, diabetes, HEAT assessment tool, and lifestyle interventions.
Danuglipron Reduces HbA1C Levels, Fasting Plasma Glucose in Type 2 Diabetes
Investigators examined changes in HbA1c levels and fasting plasma glucose, and adverse events in individuals with type 2 diabetes following danuglipron treatment.
Earlier Age at Type 2 Diabetes Onset May Lead to Higher Dementia Risk
In a large population-based cohort study, researchers evaluated whether the association of prediabetes with dementia is explained by the intervening onset of diabetes.
Brenzavvy Now Available for Adults With Type 2 Diabetes
Brenzavvy is an oral sodium-glucose cotransporter 2 inhibitor.
- Loading...
Loading...
Loading... 
Loading...